Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

MLA

Dickinson, Michael J., et al. “Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.” The New England Journal of Medicine, vol. 387, no. 24, Dec. 2022, pp. 2220–31. EBSCOhost, https://doi.org/10.1056/NEJMoa2206913.

APA

Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., Wu, S.-J., Cartron, G., Hertzberg, M., Sureda, A., Perez-Callejo, D., Lundberg, L., Relf, J., Dixon, M., Clark, E., … Hutchings, M. (2022). Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, 387(24), 2220–2231. https://doi.org/10.1056/NEJMoa2206913

Chicago

Dickinson, Michael J, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Gloria Iacoboni, Cyrus Khan, et al. 2022. “Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.” The New England Journal of Medicine 387 (24): 2220–31. doi:10.1056/NEJMoa2206913.